Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

How The Red-Hot Obesity Space Could Help Eli Lilly Join The 1,000 Club

Lilly's new weight-loss drug could top $62 billion in 2030 sales, an analyst said Friday as he boosted his price target on Eli Lilly stock to 1,000.

Investors Business Daily

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

20 Highest-Grossing Biotech Stocks: Giants Driving Innovation and Growth

Biotech stocks offers the potential for significant returns driven by breakthrough discoveries and advancements in healthcare, agriculture, and other industries.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Viking Therapeutics Catapults 121% As Weight-Loss Drug Beats Out Lilly's Zepbound

A weight-loss drug from Viking topped Lilly's Zepbound in a midstage study Tuesday. Viking stock more than doubled, while Lilly shares fell.

Investors Business Daily

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Investors Business Daily

Weight-loss drug use could boost GDP in US by 1%, says Goldman Sachs

Some analysts predict market could reach $100bn a year by end of decade with Eli Lilly and Ozempic maker Novo Nordisk leading

The Guardian - US

CNBC To Air Documentary on Weight-Loss Drug Ozempic

Melissa Lee reports for ‘Big Shot: The Ozempic Revolution,’ debuting Feb. 29

Multichannel News

inkl

Read news from The Economist, FT, and more,
with one subscription

Europe's Most Valuable Stock Is a Must-Own Near 52-Week Highs

Europe's Most Valuable Stock Is a Must-Own Near 52-Week Highs

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's stock market, too. Here's why NVO is a must-own stock.

It's Not Too Late to Buy Eli Lilly Stock. Here's Why.

It's Not Too Late to Buy Eli Lilly Stock. Here's Why.

J.P. Morgan thinks sales of weight-loss drugs could exceed $100 billion by 2030. That's good news for Eli Lilly, which is now the largest pharma company by market capitalization and the 9th-biggest S&P 500 stock. Here's why LLY stock looks poised to put on even more weight in the months…

Weight-loss drugs need to become cheaper, says AstraZeneca boss

Weight-loss drugs need to become cheaper, says AstraZeneca boss

Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill

The Guardian - UK

Novo Nordisk vs. Eli Lilly: Which Mega-Cap Healthcare Stock is a Better Buy for 2024?

Novo Nordisk vs. Eli Lilly: Which Mega-Cap Healthcare Stock is a Better Buy for 2024?

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?

Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record

Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record

Amgen stock slumped Monday — as Eli Lilly stock hit a record high — after the company unveiled preclinical results for its weight-loss drug.

Investors Business Daily

Novo Nordisk To Up Production Capacity As Parent Buys Catalent

Novo Nordisk To Up Production Capacity As Parent Buys Catalent

Shares in Novo Nordisk rose after its parent, Novo Holdings, said it has agreed to by contract drug manufacturer Catalent for $11.5 billion in cash.

Investors Business Daily

Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review

Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review

The stock market largely took a huge earnings week in stride, along with Fed chief Powell and a hot jobs report hitting rate-cut odds.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Rises On Surprise Jobless Claims; Amazon, Apple To Report

The Dow Jones rose Thursday on a surprise jump in initial unemployment claims. Magnificent Seven stocks Amazon and Apple will report late.

Pharma Stock Analysis: Buy, Hold, or Sell These 4?

Amid rising global medical needs, an aging population, and technological advancements, the pharmaceutical industry is expected to witness robust growth over the coming years. Given this positive backdrop, let’s analyze the investment prospects of pharma stocks Madrigal (MDGL), Pfizer (PFE), Astellas (ALPMY), and Novo Nordisk (NVO). Read on.

Investors Business Daily

Stock Market Sells Off After Powell Talks Down March Rate Cut; Fed Holds Rates Steady

The stock market weakened in afternoon trading on Wednesday following Fed chief Jerome Powell's comments Wednesday afternoon.

The Guardian - UK

Obesity drug boom pushes Novo Nordisk shares to record high

Market value of Danish drugmaker behind Wegovy and Ozempic tops $500bn as demand soars

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novo Stock Surges Out Of A Buy Zone On Ozempic's Commanding Sales Beat

Novo Nordisk stock popped Wednesday after its biggest moneymaker, a diabetes drug called Ozempic, put up a commanding fourth-quarter beat.

Investors Business Daily

Tech Dives, Dow Jones Rises Ahead Of Today's Fed Decision; AMD, Google, Microsoft, Nvidia, Tesla Slide

The Dow Jones rose ahead of today's Fed decision and Fed Chair Jerome Powell's comments. AMD, Google, Tesla and Microsoft sold off.

International Business Times

Weight-loss Drug Maker Novo Nordisk's Profit Surges As Sales Boom

Danish pharmaceutical giant Novo Nordisk posted bumper profits for 2023 on Wednesday, driven by blockbuster sales of diabetes and obesity treatments that helped it become Europe's most valuable company.

The Guardian - UK

UK house prices rise in January, Novo Nordisk obesity drug sales surge – as it happened

Nationwide says housing market looks ‘more positive’ as prices rise 0.7%; the Danish maker of Ozempic and Wegovy predicts further strong growth in 2024

Investors Business Daily

Dow Jones Falls After Key Economic Data; Alphabet, AMD, Microsoft To Report

The Dow Jones Industrial Average dropped Tuesday on key economic data. Alphabet, Microsoft and AMD will report earnings late.

Investors Business Daily

Dow Jones Futures: Fed Meeting On Deck; AI Stock Supermicro Surges 10% On Earnings Beat

Dow Jones futures: The stock market surged Monday ahead of the two-day Fed meeting. AI stock Supermicro soared on an earnings beat.

Investors Business Daily

Stocks Pick Up Afternoon Steam To End At Day's Highs; Dow And S&P Close At New Records

The stock market rallied into the close with the major indexes strengthening in afternoon trading.

1 … 15 16 17 18

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

299,979 stories

120,478 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play